SIDE EFFECTS OF PROTON PUMP INHIBITORS WITH LONG-TERM USE. A REVIEW OF RECENT PUBLICATIONS
Main Article Content
Abstract
Proton pump inhibitors (PPIs) are the most effective drugs for the treatment of acid-related diseases. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. In recent years, a number of foreign reviews have been published that examine the links between long-term use of PPIs and a number of diseases/conditions, and in the domestic literature there were no reviews devoted to the safety of PPIs with their long-term use, in connection with which we conducted a search in the PubMed and Scopus information databases for publications devoted to the safety of PPI use, including sources up to 11/15/2023. Our search revealed not only an increased risk of infections and fractures due to osteoporosis, but also probable kidney pathology, possible electrolyte disturbances, the risk of cancer, cardiovascular risk and a number of rare but clinically significant side effects associated with long-term PPI therapy. In the current review, we examined publications from the PubMed and Scopus databases devoted to the safety of long-term use of PPIs for the period from 16.11.2023 to 31.12.2024. Publications of the last year confirm the association of long-term PPI therapy with an increased risk of infections, osteoporosis and associated fractures, electrolyte disturbances and kidney pathology, cancer, and CVD. In addition to those described earlier, publications of the last year discuss an increased risk of rhythm disturbances, allergies, inflammatory bowel diseases, and non-alcoholic fatty liver disease.
Knowledge (and not denial) of the side effects of PPIs with their long-term use is important not only for a gastroenterologist and therapist, but taking into account the comorbidity / multimorbidity of patients and for doctors of other specialties. PPIs should be used strictly according to indications in accordance with clinical guidelines and for the shortest possible duration and at the minimum effective dose to relieve mild to moderate symptoms. Patients with clear indications (Barrett's esophagus, erosive esophagitis C/D and a number of others in accordance with clinical guidelines) should continue long-term use of PPIs under regular control/monitoring of side effects, taking into account the patient's comorbidity/multimorbidity.
Keywords
Author Biographies
Дмитрий Иванович Трухан,
Dmitry I. Trukhan
MD, PhD, docent. Professor of the Department of Internal Medicine and Polyclinic Therapy.
Сергей Николаевич Филимонов,
doctor of medical sciences, professor, head of the department of human ecology, public health and healthcareArticle Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Refl ux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(4): 70-97. Russian (Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Т. 30, № 4. С. 70-97.) doi: 10.22416/1382-4376-2020-30-4-70-97
Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019; 9: 1142. doi: 10.3389/fneur.2018.01142
Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.Aliment Pharmacol Ther. 2021; 54(2): 129-143. doi: 10.1111/apt.16407
Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. Arq Gastroenterol. 2022; 59(2): 219-225. doi: 10.1590/S0004-2803.202202000-40
Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm. 2023; 80(8): 487-494. doi: 10.1093/ajhp/zxad009
Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023; 59(2): 115-127. doi: 10.4068/cmj.2023.59.2.115
Trukhan DI. Drug safety: focus on long-term therapy with proton pump inhibitors. Probable side effects. Clinical analysis in general medicine. 2024; 5 (1): 48–56. Russian (Трухан Д.И. Лекарственная безопасность: в фокусе долгосрочная терапия ингибиторами протонной помпы. Вероятные побочные эффекты //Клинический разбор в общей медицине. 2024. Т. 5, № 1. С. 48-56.) doi: 10.47407/kr2023.5.1.00360
Trukhan DI, Tarasova LV, Stepashina TE. The Focus on Increased Risk of Fractures in their Prolonged Use. Acta medica Eurasica. 2024;1: 93–100. Russian (Трухан Д.И., Тарасова Л.В., Степашина Т.Е. Ингибиторы протонной помпы: в фокусе повышенный риск переломов при длительном применении //Acta medica Eurasica. 2024. № 1. С. 93-100.) doi: 10.47026/2413-4864-2024-1-93-1
Trukhan DI, Viktorova IA. Side effects of proton pump inhibitors with long-term use: focus on the urinary system. Medical alphabet. 2024; (5): 36-42. Russian (Трухан Д.И., Викторова И.А. Побочные эффекты ингибиторов протонной помпы при длительном применении: в фокусе мочевыделительная система //Медицинский алфавит. 2024. № 5. С. 36-42.) doi: 10.33667/2078-5631-2024-5-36-42
Trukhan DI. Drug safety: focus on long-term therapy with proton pump inhibitors. Possible side effects. Clinical analysis in general medicine. 2024; 5(2): 106-112 Russian (Трухан Д.И. Лекарственная безопасность: в фокусе – долгосрочная терапия ингибиторами протонной помпы. Возможные побочные эффекты //Клинический разбор в общей медицине. 2024. Т. 5, № 2. С. 106-112.) doi: 10.47407/kr2023.5.2.00397
Trukhan DI, Filimonov SN. Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality: A review. Consilium Medicum. 2024; 26(1): 37-42. Russian (Трухан Д.И., Филимонов С.Н. Кардиоваскулярный риск при длительном применении ингибиторов протонной помпы: миф или реальность. Consilium Medicum. 2024. Т. 26, № 1. С. 37-42.) doi: 10.26442/20751753.2024.1.202532
Wu LH, Wang JL, Liu YH, Su CC, Yang YK, Lin S-J, Cheng C-L. Hospitalized patients on proton pump inhibitors for stress ulcer prophylaxis have a higher risk of Clostridioides difficile infection compared with those on histamine-2 receptor antagonists. J Hosp Infect. 2024; 154: 9-17. doi: 10.1016/j.jhin.2024.09.016
Zeng R, Ma Y, Zhang L, Luo D, Jiang R, Wu H, et al. Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study. Elife. 2024; 13: RP94973. doi: 10.7554/eLife.94973
Kommer A, Kostev K, Schleicher EM, Weinmann-Menke J, Labenz C. Proton pump inhibitor use and bone fractures in patients with chronic kidney disease. Nephrol Dial Transplant. 2024; 40(1): 173-181. doi: 10.1093/ndt/gfae135
Alanazi AS, Almutairi H, Gupta JK, Mohanty D, Rath D, AlOdan AA, et al. Osseous implications of proton pump inhibitor therapy: An umbrella review. Bone Rep. 2024; 20: 101741. doi: 10.1016/j.bonr.2024.101741
Kim SG, Cho JM, Han K, Joo KW, Lee S, Kim Y, et al. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study. BMJ Open. 2024; 14(1): e078032. doi: 10.1136/bmjopen-2023-078032
Zhang Y, Liu M, Zhu Z, Chen H. Proton pump inhibitors use is associated with a higher prevalence of kidney stones: NHANES 2007-2018. BMC Public Health. 2024; 24(1): 1215. doi: 10.1186/s12889-024-18710-8
Zheng X, Zhou Q, Zhu Y, Xu L, Xu D, Lv J, Yang L. Association between preoperative proton pump inhibitor use and postoperative acute kidney injury in patients undergoing major surgery. Ren Fail. 2024; 46(2): 2379596. doi: 10.1080/0886022X.2024.2379596
Lee YJ, Kim J, Yu DH, Je NK, Rhee H. Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study. Sci Rep. 2024; 14(1): 31477. doi: 10.1038/s41598-024-83321-7
Parmar MP, Kaleem S, Samuganathan P, Ishfaq L, Anne T, Patel Y, et al. Impact of Proton Pump Inhibitors on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review. Cureus. 2023; 15(12): e49883. doi: 10.7759/cureus.49883
Bobrowicz M, Pachucki J, Popow M. Hypomagnesaemia leading to parathyroid dysfunction, hypocalcaemia, and hypokalaemia as a complication of long-term treatment with a proton pump inhibitor – a literature review. Endokrynol Pol. 2024; 75(4): 359-365. doi: 10.5603/ep.98576
Liu Q, Wang X, Engstrand L, Sadr-Azodi O, Fall K, Brusselaers N. Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study. BMJ Open. 2024; 14(7): e079591. doi: 10.1136/bmjopen-2023-079591
Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J. 2019; 15: 214-219. doi: 10.14797/mdcj-15-3-214
Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021; 76(1): 13-21. doi: 10.1016/j.therap.2020.06.019
Pannoi T, Promchai C, Apiromruck P, Wongpraphairot S, Dong YH, Yang C-C, Pan W-C. Risk of circulatory diseases associated with proton-pump inhibitors: a retrospective cohort study using electronic medical records in Thailand. Peer J. 2024; 12: e16892. doi: 10.7717/peerj.16892
Li ZH, Zhong WF, Qiu CS, Yang P, Song WQ, Shen D, et al. Association between regular proton pump inhibitors use and cardiovascular outcomes: A large prospective cohort study. Int J Cardiol. 2024; 395: 131567. doi: 10.1016/j.ijcard.2023.131567
Foresta A, Fernandez LO, Torrigiani G, Schena S, Roncaglioni MC, Nobili A, et al. Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study. Drugs Aging. 2024; 41(3): 239-249. doi: 10.1007/s40266-024-01097
Fan W, Liu H, Shen Y, Hong K. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients. Cardiovasc Drugs Ther. 2024; 38(3): 517-525. doi: 10.1007/s10557-023-07425-4
Eroglu TE, Coronel R, Gislason GH. Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. Eur Heart J Cardiovasc Pharmacother. 2024; 10(5): 413-419. doi: 10.1093/ehjcvp/pvae020
Mitsuboshi S, Imai S, Kizaki H, Hori S. Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database. J Infect. 2024; 89(2): 106202. doi: 10.1016/j.jinf.2024.106202
Sun Y, Zhang A, Zuo M, Chen J, Zhu L. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database. J Gastroenterol Hepatol. 2024; 39(2): 289-296. doi: 10.1111/jgh.16411
Ohyama K, Iida M, Akiyama S, Yamazaki H, Hori Y. Time-to-onset Analysis of Rhabdomyolysis due to Different Proton Pump Inhibitors Using a Pharmacovigilance Database. In Vivo. 2024; 38(3): 1285-1291. doi: 10.21873/invivo.13567
Duarte GJ, Lopez J, Sosa F, Molina G, Shaban M, Mark J, et al. Proton pump inhibitors and cardiovascular risk: a critical review. Future Cardiol. 2024; 20(14): 779-794. doi: 10.1080/14796678.2024.2412910
Khawaja M, Thakker J, Kherallah R, Kitakaze M, Jneid H, Angiolillo DJ, Birnbaum Y. Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers. Cardiovasc Drugs Ther. 2024; 38(1): 181-189. doi: 10.1007/s10557-022-07358-4
Ortiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA, López-Fuentes D, Nava Mesa MO. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plast. 2018; 2018: 5257285. doi: 10.1155/2018/5257285
Khan Z, Mehan S, Saifi MA, Gupta GD, Narula AS, Kalfin R. Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks. Curr Alzheimer Res. 2024; 20(11): 739-757. doi: 10.2174/0115672050289946240223050737
Pourhadi N, Janbek J, Jensen-Dahm C, Gasse C, Laursen TM, Waldemar G. Proton pump inhibitors and dementia: A nationwide population-based study. Alzheimers Dement. 2024; 20(2): 837-845. doi: 10.1002/alz.13477
Hong JT, Jung HK, Lee KJ, Gong EJ, Shin CM, Kimet JW, et al. Potential risk of proton pump inhibitors for Parkinson's disease: A nationwide nested case-control study. PLoS One. 2023; 18(12): e0295981. doi: 10.1371/journal.pone.0295981
Bavbek S, Kepil Özdemir S, Bonadonna P, Atanaskovic-Markovic M, Barbaud A, Brockow K, et al. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper. Allergy. 2024; 79(3): 552-564. doi: 10.1111/all.15961
Yu R, Wang X, Wang H, Lu X, Yang B. Associations between Proton-Pump Inhibitor Usage, Allergy, and Asthma: An Analysis of NHANES 2005-2006. Int Arch Allergy Immunol. 2024; 185(6): 519-526. doi: 10.1159/000535156
Lim HJ, Oh IS, Noh Y, Yon DK, Shin JY. Association between proton pump inhibitors use and risk of asthma in Korea: A prevalent new-user cohort study. Medicine (Baltimore). 2024; 103(1): e36772. doi: 10.1097/MD.0000000000036772
Fossmark R, Olaisen M. Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors-A Review of Findings from Experimental Trials. Microorganisms. 2024; 12(6): 1110. doi: 10.3390/microorganisms12061110
Trukhan DI, Sulimov AF, Trukhan LYu. Comorbidity of inflammatory bowel diseases and periodontal pathology. Meditsinskiy Sovet. 2024; 18(15): 215-223. Russian (Трухан ДИ, Сулимов АФ, Трухан ЛЮ. Коморбидность воспалительных заболеваний кишечника и патологии пародонта //Медицинский совет. 2024. Т. 18, № 15. С. 215-223.) https://doi.org/10.21518/ms2024-373
Zhu J, Sun C, Li M, Hu G, Zhao XM, Chen WH. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial. Gut. 2024; 73(7): 1087-1097. doi: 10.1136/gutjnl-2023-330168
Liang Y, Meng Z, Ding XL, Jiang M. Effects of proton pump inhibitors on inflammatory bowel disease: An updated review. World J Gastroenterol. 2024; 30(21): 2751-2762. doi: 10.3748/wjg.v30.i21.2751
Choden T, Zhang H, Sakuraba A. Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease. Ann Med. 2023; 55(1): 2198775. doi: 10.1080/07853890.2023.2198775
Fossmark R, Lirhus SS, Høivik ML. The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway. Scand J Gastroenterol. 2024; 59(1): 46-51. doi: 10.1080/00365521.2023.2255710
Huang H, Liu Z, Guo Y, Zeng Y, Shen S, Xu C. Long-term Use of Proton Pump Inhibitors is Associated With An Increased Risk of Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol. 2024; 58(3): 289-296. doi: 10.1097/MCG.0000000000001847
Chenchula S, Sharma P, Ghanta MK, Amerneni KC, Rajakarunakaran P, Saggurthi P, et al. Association and Mechanisms of Proton Pump Inhibitors Use with Type-2Diabetes Mellitus Incidence in Adults: A Systemic Review and Meta-Analysis. Curr Diabetes Rev. 2024; 20(10): e120124225581. doi: 10.2174/0115733998254869231101095222
O'Mahony S, Tobin AM, Donnelly TM. Severe DRESS with myocarditis secondary to naproxen/esomeprazole. BMJ Case Rep. 2024; 17(4): e258187. doi: 10.1136/bcr-2023-258187
Li W, Yu Y, Li M, Fang Q, Jin X, Lin H, Xu J. Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis. Int J Clin Pharm. 2024; 46(6): 1381-1390. doi: 10.1007/s11096-024-01778-y
Ashfaq M, Khan AN, Alkahraman YM, Haroon MZ. Long-term proton pump inhibitors therapy and prevalence of hyperprolactinaemia: A cross-sectional study in outpatient gastroenterology clinics. J Pak Med Assoc. 2024; 74(6): 1067-1073. doi: 10.47391/JPMA.9541
Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017; 37: 19-24. doi: 10.1016/j.ejim.2016.10.007
Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020; 75: 497-507. doi: 10.1053/j.ajkd.2019.07.012
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018; 11: 1123-1134. doi: 10.1080/17512433.2018.1531703
Nguyen PV, Tamaz R. Inappropriate prescription of proton pump inhibitors in a community setting. Can J Hosp Pharm. 2018; 71: 267-271
Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm. 2020; 42: 174-183. doi: 10.1007/s11096-019-00955-8
Agreus L, Borgquist L, Tsoposidis A, Wallenius V, Kostic S, Lundell L, Lindberg G. Significant over- and misuse of PPIs. Lakartidningen. 2021; 118: 20220.
Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021; 8: e000563 doi: 10.1136/bmjgast-2020-000563
Vorobyeva NM, Tkacheva ON. Safety of antithrombotic therapy in cardiological practice: how to protect tunica mucosa of gastrointestinal tract? Therapy. 2022; 4: 134-140. Russian (Воробьева Н.М., Ткачева О.Н. Безопасность антитромботической терапии в кардиологической практике: как защитить слизистую желудочно-кишечного тракта? //Терапия. 2022. № 4. С. 134-140. doi: 10.18565/therapy.2022.4.134-140
Zhou M, Zhang J, Liu J, Smith SC Jr, Ma C, Ge J, et al. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy. Mayo Clin Proc. 2022; 97(4): 682-692. doi: 10.1016/j.mayocp.2021.11.037
Tkacheva ON, Vorobyeva NM, Kotovskaya YuV, Runikhina NK, Strazhesco ID, Villevalde SV, et al. Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Cardiovascular Therapy and Prevention. 2021; 20(3): 2847. Russian (Ткачёва О.Н., Воробьёва Н.М., Котовская Ю.В., Рунихина Н.К., Стражеско И.Д., Виллевальде С.В., и др. Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии //Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 3. С. 2847.) doi: 10.15829/1728-8800-2021-2847
Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021; 10: 23-41. Russian (Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты //Терапия. 2021. № 10. С. 23-41. doi: 10.18565/therapy.2021.10.23-41
Rossi A, Perrella L, Scotti S, Olmastroni E, Galimberti F, Ardoino I, et al. Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. J Clin Med. 2024; 13(20): 6283. doi: 10.3390/jcm13206283
Ben-Eltriki M, Chhabra M, Cassels A, Wright JM. Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events? Curr Drug Saf. 2024; 19(2): 244-247. doi: 10.2174/1574886318666230726124540
Xia B, He Q, Smith FG, Gkoutos VG, Nirantharakumar K, Kuo ZC, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nat Commun. 2024; 15(1): 3591. doi: 10.1038/s41467-024-48007-8